All articles by Johney


PPD and Clinical Ink partner on process for lupus assessment

US contract research organisation PPD and clinical technology company Clinical Ink have jointly developed a systemic lupus erythematosus (SLE) assessment review process.

Merck reports data from Phase III KEYNOTE-598 trial

Merck has reported first-time data from the Phase 3 KEYNOTE-598 trial analysing KEYTRUDA, its anti-PD-1 therapy, along with ipilimumab (Yervoy) as against KEYTRUDA monotherapy as a first-line treatment for patients suffering with NSCLC without EGFR or ALK genomic tumour aberrations and whose tumours express PD-L1.

Abivax doses first patient in Phase II/III Covid-19 clinical trial

French biotechnology company Abivax has dosed the first patient in its Phase II/III study of ABX464 in Covid-19 patients at the University Hospital Center in Nice, France.

IQVIA and LMC Manna Research to launch Prime Site in Canada

IQVIA has entered a strategic alliance with LMC Manna Research to launch its first Prime Site for clinical investigation in Canada.

AES launches patient-transfer programme for biopharma companies

Accelerated Enrollment Solutions (AES) has launched new patient-transfer programme to assist biopharmaceutical companies amid coronavirus (Covid-19) pandemic.

Novavax and Nucleus partner to launch Covid-19 vaccine trials

US-based biotechnology company Novavax has partnered with Nucleus Network to initiate the clinical trials for its Covid-19 vaccine SARS-CoV-2 Recombinant Spike Protein Nanoparticle (NVX-CoV2373).

Aurora trial reveals possible drug to treat Lupus kidney disease

Aurora, a Phase III global trial presented by the National Kidney Foundation (NKF), has revealed a possible drug for the treatment of lupus kidney disease.

BELLUS Health completes patient enrolment in trial of BLU-5937

Canadian biopharmaceutical firm BELLUS Health has completed patient enrollment for its dose-escalation, placebo-controlled Phase II RELIEF trial of BLU-5937 in patients with refractory chronic cough.

Algernon retains Novotech for trial of Ifenprodil in Covid-19 patients

Algernon Pharmaceuticals has retained Novotech, an Asia-Pacific clinical research organisation (CRO), for a planned Phase II clinical trial of Ifenprodil (NP-120) to treat coronavirus (Covid-19) patients.

NantKwest doses first patient in Merkel cell carcinoma therapy trial

NantKwest has dosed the first patient in a Phase II trial of natural killer cells for second and third-line Merkel cell carcinoma (MCC) in patients who are refractory to immune checkpoint inhibitors.